MedTrace Logo

Real World Effectiveness of Ustekinumab in Induction and Maintenance Therapy for Crohn´s Disease

NCT03108326 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 900

Last updated 2018-07-13

No results posted yet for this study

Summary

"RUN-CD" is an investigator initiated "Non interventional Trial" on biologics in Crohn´s Disease (CD) patients in Germany with a prospective documentation of effectiveness in induction and maintenance therapy of biologics, especially of Ustekinumab, with a special interest on predictors of long-term responses and favorable disease outcome and documentation of severe side effects caused by the therapy with biologics.

Conditions

  • Crohn Disease

Interventions

BIOLOGICAL

Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra

The data of Crohn´s Disease (CD)-patients on Ustekinumab will be compared in an explorative analysis with CD-patients on other Biologics.

Sponsors & Collaborators

  • Ced Service GmbH

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-15
Primary Completion
2023-03-31
Completion
2023-03-31
FDA Drug
Yes

Countries

  • Germany

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03108326 on ClinicalTrials.gov